A study looking at mortality rates from major cancer types may help inform cancer prevention and treatment strategies, and lead to a reduction to the global cancer disparities seen today.
John Nakayama, MD, discusses what the evolution of endometrial cancer treatment has looked like in recent years.
Yazan Samhouri, MD, discusses his impressions of the TRIANGLE clinical trial presented at the 2022 American Society of Hematology Annual Meeting.
Sattva S. Neelapu, MD will discuss chimeric antigen receptor T-cell therapy will in lymphoma iduring a session at the SOHO 2022 Annual Meeting.
Closing their discussion, the panel highlights unmet needs in the management of relapsed/refractory multiple myeloma and shares clinical pearls for community physicians.
In the second article of this series, Chandler H. Park, MD, a genitourinary oncologist at Norton Cancer Institute, reviews recently updated data on advanced renal cell carcinoma treatments.
Catherine C. Coombs, MD, discusses unmet needs and offers advice for community oncologists treating patients with relapsed/refractory chronic lymphocytic leukemia.
Rogerio C. Lilenbaum, MD, discusses molecular panels and other testing for patients with nonsquamous non-small cell lung cancer.
Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.
The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.
Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.
Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.
Jimmy Caudell, MD, PhD, discusses the overall incidence of human papillomavirus-positive and negative oropharyngeal cancers in the United States.
Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD.
Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.
With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.
Luv N. Hajirawala, MD, discusses the findings from a retrospective analysis of the Surveillance, Epidemiology and End Results database looking at patients with stage III colon cancer.
Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.
A real-world guide to best practices in treating neuroendocrine tumors can improve patient outcomes.
For patients with hepatocellular carcinoma treated in the second-line setting, the combination of regorafenib and nivolumab following 2 cycles of regorafenib monotherapy appeared safe, according to phase 1/2a study.
Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.
Terry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.
Joseph M. Curry, MD, discusses the introduction of immune checkpoint inhibitors for the treatment of patients with head and neck cancers.
Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
Carole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.
Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Tapan Kadia, MD, discusses the recent and upcoming changes in treatment of acute myeloid leukemia for patients who are not candidates for intensive remission induction therapy.